Can Monoamine-Based Therapies Be Improved?

Monoamine-based therapies that selectively target serotonin, norepinephrine, or dopamine uptakeare effective as antidepressants. However, many depressed patients do not achieve remission withthese single-action agents. Treatment strategies that target more than one neurotransmitter, eitherthrough augmentation, combination treatment, or the development of single agents with dual or triplereuptake mechanisms, may prove to be even more effective than traditional antidepressants and meritfurther research.